What the FDA labels say about taking them together
Methylene blue and ziprasidone
Ziprasidone's FDA label of July 20, 2026 names methylene blue in its contraindications section; the methylene blue label PlainMeds reads does not name ziprasidone. The ziprasidone label: “Inhibitors (MAOIs) Ziprasidone is contraindicated in patients taking, or within 14 days of stopping, MAOIs because of an increased risk of serotonin syndrome.”
Check it at the source: the methylene blue FDA label on DailyMed (effective May 28, 2025, American Regent, Inc.); the ziprasidone FDA label on DailyMed (effective July 20, 2026, Apotex Corp.).
What does the methylene blue label say about ziprasidone?
Methylene blue's label (effective May 28, 2025) does not name ziprasidone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (PROVAYBLUE), NDA204630 (Provepharm Sas), as published by American Regent, Inc., effective May 28, 2025 (SPL set 4f6848e5-35ed-4046-b13c-3032b5ba3232), via openFDA; the full label on DailyMed
What does the ziprasidone label say about methylene blue?
Ziprasidone label, contraindicationsInhibitors (MAOIs) Ziprasidone is contraindicated in patients taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.4 ), Drug Interaction ( 7.3 )].
Ziprasidone label, warnings and precautionsIf it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking ziprasidone, discontinue ziprasidone before initiating treatment with the MAOI [see Contraindications ( 4.3 ), Drug Interactions ( 7.3 )].
Source: FDA drug label (Geodon, NDA020825), Viatris Specialty LLC, effective January 15, 2025 (SPL set a2b4cc65-6a6d-49c4-adfc-a4458562a167), via openFDA
Source: FDA drug label (ziprasidone hydrochloride), Apotex Corp., effective July 20, 2026 (SPL set ccfd5ba2-7271-f3dd-4c98-7418c1a4b54a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Methylene blue | Ziprasidone | |
|---|---|---|
| Labeled for | n/a | Bipolar disorder, Schizophrenia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.269 per capsule 20 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once